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Long-acting β2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments
of chronic obstructive lung diseases. Although no speciﬁc indications concerning the choice of one molecule
rather than another are provided by asthma and COPD guidelines, they present different pharmacological
properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic
efﬁcacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efﬁcacy.
From a clinical perspective, in the presence of low β2-adrenoceptors availability, like in inﬂamed airways, a full
agonist can maintain its bronchodilatory and non-smooth muscle activities while a partial agonist may be less
effective. Furthermore, formoterol presents a faster onset of action than salmeterol. This phenomenon, combined
with the molecule safety proﬁle, leads to a prompt amelioration of the symptoms, and allows using this drug in
asthma as an “as needed” treatment in patients already on regular treatment. The fast onset of action and the full
agonismof formoterol need to be considered in order to select the best pharmacological treatment of asthma and
COPD.
© 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
1. Introduction
Since the 1990s, Long-Acting β2-adrenoceptor Agonists (LABAs)
have been considered as milestones in the treatment of Chronic
Obstructive Pulmonary Disease (COPD) and asthma. In COPD, LABAs,
formoterol and salmeterol, reduce airways obstruction, lung hyper-
inﬂation and exacerbations, improve exercise tolerance, ameliorate
symptoms, enhance health-related quality of life [1–4] and offer a
potential survival advantage [5]. In asthma, where LABAs are strictly
recommended to be used in association with inhaled corticosteroids
(ICS) [6], as results of the above mentioned effects, LABAs increase
the probability of achieving disease control with a lower concomitant
exposure to ICS as compared to ICS alone [7,8]. Although no speciﬁc
indications concerning the choice between salmeterol or formoterol
are provided by COPD and asthma guidelines [4,9], these drugs differ
in pharmacokinetics (what the body does to the drug) and pharmaco-
dynamics (what the drug does to the body).
The aim of this paper is to review formoterol and salmeterol
pharmacological properties and related different clinical employment
possibilities.
2. Formoterol and salmeterol: differences in pharmacokinetics
A great advantage of inhalation drug therapy is the possibility to
reach directly the target organ, reducing the systemic drug exposure
and related adverse effects. LABAs have well-known pharmacological
and clinical proﬁles with a few but essential differences [10,11]
(Table 1).
The bronchodilatory effect of a LABA is a function of drug
concentration at the bronchial smooth muscle cells and the degree
of activation of the β2-adrenoceptor. The onset and duration of
bronchodilation are inﬂuenced by the time it takes for an inhaled
LABA to achieve and maintain effective concentration at the
receptor site [11]; both of these are related to physicochemical
characteristics of the LABAs. Differences in physicochemical
properties between formoterol and salmeterol may explain faster
onset of action of formoterol [12]. Relatively high water solubility
and moderate lipophilicity ensure rapid access of inhaled formoterol
to the β2-adrenoceptor on bronchial smooth muscle cells and rapid
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bronchodilation. In contrast, low water solubility and high lipophi-
licity of salmeterol results in its slower onset of action [12]. Addition-
ally, the uptake of formoterol by airway smooth muscle cells is
dependent on organic cation transporter 3 (OCT3); in contrast, the
uptake of non-charged lipophilic salmeterol is independent of OCTs
transporters. Importantly, corticosteroids inhibit OCT3 and by that
may increase the presence of formoterol at cell membrane β2-
adrenoceptor thus potentiating formoterol effect [13,14].
Lipophilic characteristics of salmeterol and formoterol also explain
prolonged duration of bronchodilation by these drugs [12], with a
somewhat shorter duration of action for fomoterol than salmeterol in
ex vivo experiments in small airways [12], however with no difference
in duration of effect shown in a clinical study in asthmatic patients
[15]. The lipophilicity of both formoterol and salmeterol is sufﬁcient to
allow them to easily enter and be stored in cell membranes, making a
depot fromwhich drugs are available to β2-adrenoceptors on bronchial
smooth muscle cells for a prolonged period of time [11]. This is in
contrast to short-acting β2-adrenoceptor agonists (such as salbutamol
and terbutaline) which after inhalation are cleared from the tissue
more rapidly due to their high water solubility. This was clearly
demonstrated by Jeppsson et al. who showed that the relaxing effect
of formoterol and salmeterol on isolated guinea pig tracheal smooth
muscle pre-contracted with carbachol was less readily reversed
by washing procedure than that of hydrophilic and short-acting
salbutamol [16].
3. Formoterol and salmeterol: differences in pharmacodynamics
3.1. Bronchodilatory effects
The β2-adrenoceptor agonists are the most effective broncho-
dilators because they are functional antagonists of airway smooth
muscle contraction irrespective of the constricting stimulus. The
β2-adrenoceptors are distributed along the entire bronchial tree, in
both large and small airways. Smooth-muscle relaxation results
from coupling of the β2-adrenoceptor, through the stimulatory Gs
protein alpha subunit to adenylate cyclase in airway smooth muscle,
which in turn increases the concentration of intracellular cyclic
adenosine monophosphate (cAMP) [17]. cAMP acts through an
intracellular network that is primarily related to protein kinase A
(PKA) that leads to a down regulation or an up regulation of different
molecular pathways that have smooth muscle relaxation as the
principal endpoint. These mechanisms are complex [18,19], and
some aspects are not completely understood in airway cells [19].
However, it is known that stimulation of β2-adrenoceptor by
structurally different agonists results in stabilisation of different
active states of the receptor and this may lead to activation of several
different signalling pathways [20], including activation of inhibitory
Gi protein which opposes Gs activation [21,22], resulting in decreased
cAMP accumulation and the impairment of β2-adrenoceptor-mediated
bronchodilation [23]. Thus, the degree of β2-adrenoceptor activation by
structurally different agonists may be determined by the extent of Gi
activation [22]. The differences in molecular structure of formoterol
and salmeterol are responsible for differences in the interaction of
these drugs with β2-adrenoceptor and therefore differences in intrinsic
efﬁcacy that is high for formoterol and low for salmeterol (Fig. 1).
Formoterol binds to β2-adrenoceptor with high afﬁnity and
triggers effective signal transduction while salmeterol does not
lead to full signal transduction and therefore salmeterol is a partial
agonist, i.e. has a lower intrinsic efﬁcacy, compared to formoterol.
This explains higher extent of maximal dilation by formoterol of
severely contracted tracheobronchial smooth muscle than that
by salmeterol (independent of concentration applied) shown in
isolated guinea pig trachea and in human bronchus [23,24].
Signiﬁcantly, the differences in intrinsic efﬁcacy between formoterol
and salmeterol have implications for the bronchodilatory effects of
these LABAs under inﬂammatory conditions. Accordingly, while a
full agonist can show a full effect both in normal airway smooth
muscles (where there is a reserve of β2-adrenoceptors) and in
inﬂamed tissues (where the number of fully functioning β2-
adrenoceptors may be limited), partial agonist may be not able to
reach full effects in inﬂamed tissue, disregarded of how high doses
are used. Adner et al. [25] showed that the maximal relaxation of
carbachol-contracted mouse trachea segment by salmeterol was
decreased by 40% by 4-day pretreatment with proinﬂammatory
cytokines (TNFα and IL-1β) while this decrease was only 16%
for formoterol. One likely mechanism involved is the cytokine-
induced increased expression of cyclooxygenase (COX-2) leading
to heterologous desensitisation of β2-adrenoceptor impairing to a
greater extent effects of a partial agonist, salmeterol, than those of
full agonist, formoterol. Another possible mechanism is that receptor
stimulation by salmeterol activates Gi protein to a greater extent,
and that pro-inﬂammatory cytokines – through the up-regulation
of the Gi signalling [26] – attenuate salmeterol responses to a greater
extent than responses of formoterol. Interestingly, the concomitant
treatment with a glucocorticosteroid, budesonide, blocked the
cytokine-induced increased expression of COX-2 and prevented the
Table 1
Effects of LABAs.
Stimulating effect Inhibitory effect
Airway smooth muscle
Relaxation +
Proliferation +
Mucociliary clearance +
Ciliary beat frequency +
Alveolar ﬂuid clearance +
Neutrophil adhesion +
Neutrophil chemotaxis +
Neutrophil apoptosis +
Eosinophil apoptosis +
Neutrophil activation +
Neutrophil ROS production +
Eosinophil ROS production +
Mast cell mediator release +
Eosinophil mediator release +
T-lymphocyte cytokine release +
Fig. 1. The bronchodilator gray playingﬁeld. The black hexagon represents formoterol and
the white hexagon salmeterol. The imaginary zone (upper right triangle) identiﬁes the
drugs with high power expressed by intrinsic efﬁcacy and duration of action underline
by lipophilicity; of course, the onset of action is related to water solubility which is not
presented in this ﬁgure. However, it's worth considering that while lipophilicity per se
does not guarantee a long duration of action, on the other hand may have several
disadvantages too.
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cytokines-induced impairment of tracheal relaxation and β2
adrenoceptor/cAMP signalling for formoterol but not for salmeterol
[25]. This suggests differences between these drugs in coupling/
activation of β2-adrenoceptor and/or signal transduction from
this receptor. The possible explanation of no improvement of
salmeterol responses by budesonide is a greater involvement of
the inhibitory Gi protein signalling from the receptor stimulated
with salmeterol than with formoterol and earlier described
insensitivity of Gi protein to glucocorticosteroid treatment [27].
From the clinical perspective, these results suggest that the
combined treatment with budesonide/formoterol could guarantee
an efﬁcient bronchodilation during periods with increased
inﬂammation such as during asthma exacerbations, whereas
effects of combination treatment with a glucocorticosteroid and
salmeterol may be less efﬁcient during inﬂammation.
3.2. Non-bronchodilatory effects
3.2.1. Mucociliary clearance
The β2-adrenoceptor agonists may also have clinically relevant
effects not related to bronchodilation per se. It is well known
that β2-adrenoceptor agonists increase ciliary beat frequency and
stimulate mucus clearance [28–30]. The ciliary beat frequency was
shown to be signiﬁcantly reduced in nasal epithelium samples from
subjects with COPD and subjects with pneumonia compared to
healthy subjects while salmeterol applied ex vivo in these samples
increased ciliary beat frequency in concentration-dependent
manner in all subjects [31]. Recently, single inhaled dose of
formoterol (12 μg) was shown to enhance mucus clearance in mild/
moderate COPD patients compared to placebo and tiotropium
(18 μg) or salbutamol (200 μg) [32]. Furthermore, in that study
treatment for 14 days with tiotropium retarded mucus clearance
while this was not observed with formoterol suggesting that
formoterol sustains its mucociliary effect during 14 days treatment.
It is clear that to increase the mucociliary clearance by β2-
adrenoceptor agonists may enhance airway clearance of ICS when
these drugs are used in combination. This has a greater impact on
highly lipophilic ICS such as ﬂuticasone propionate, which requires
hours to be dissolved in epithelial lining ﬂuid, as compared to
budesonide which dissolves in a few minutes [33,34].
3.2.2. Airway inﬂammation and remodelling
Both formoterol and salmeterol were shown in vitro to exert
anti-inﬂammatory effects in airway smooth muscles cells. These ef-
fects are additive to, or even synergise with the anti-inﬂammatory
effects of glucocorticosteroids [35–38] and include suppression of
inﬂammatory responses induced by viral exposure [39–41] and
anti-remodelling effects. Airway remodelling is an inherent compo-
nent of asthma and includes increased numbers of airway smooth
muscle cells, goblet cell hyperplasia and ﬁbrotic rearrangement of
the airway extracellular matrix. The β2-adrenoceptor agonists have
potential to decrease the enhanced proliferation of airway smooth
muscle cells via β2-adrenoceptor-dependent mechanism as shown
for salmeterol and salbutamol [42]. Roth et al. [43] demonstrated
that even very low concentrations of formoterol (10−12–10−8 M)
effectively inhibited serum-stimulated proliferation of airway
smooth muscle cells in vitro. Activation of lung ﬁbroblasts is thought
to play a key role in the ﬁbrotic reorganisation of the extracellular
matrix in the airways and lung in asthma and COPD. Increased
synthesis of speciﬁc collagens and proteoglycans by myoﬁbroblats
is a part of this process. β2-adrenoceptor agonists may attenuate
these ﬁbrotic alterations [44]. Kelly et al. have shown that in subject
with asthma allergen inhalation results in an increase in the
numbers of submucosal myoﬁbroblasts but that formoterol in
combination with budesonide (but not budesonide monotherapy),
signiﬁcantly counteracted this increase [45]. Todorova et al. [46]
demonstrated the synergistic inhibition of serum-stimulated
proteoglycan production by formoterol and budesonide in human
lung ﬁbroblast cell line. Also the study in primary ﬁbroblasts
established from central bronchial biopsies from asthmatic patients,
has shown that formoterol in combination with budesonide has a
potential to counteract enhanced collagen production and normalise
the production of small proteoglycans which may affect collagen
structure and deposition [47].
The lung airways harbour a cellular network involved in inﬂam-
matory responses during COPD evolution. In particular neutrophils
are few in the sub-epithelial area, but largely represented in the
epithelium and in the bronchial glands [48,49] as well as in the
airway lumen. Bronchoalveolar lavage ﬂuid and induced sputum
from patients with COPD contain increased numbers of neutrophils,
which correlate with concentrations of the neutrophil chemo-
attractant, interleukin (IL)-8, and other inﬂammatory mediators,
such as leukotriene B4 (LTB4) which plays a central role in neutro-
phil activation and migration [48,50,51]. β2-adrenoceptors are
present on neutrophils, [52] and data published indicate that
salmeterol and formoterol increase cAMP in neutrophils and
therefore inhibit their adhesion, accumulation and activation [53].
This should translate into the reduction of the number of neutrophils
and decrease of their activation in the airway tissue and airway
lumen. Indeed, formoterol therapy signiﬁcantly reduced neutrophil
numbers and neutrophil chemoattractant IL-8 in sputum of severe
asthmatics compared to placebo [54]. Salmeterol was also reported
to decrease IL-8 concentration in bronchoalveolar lavage ﬂuid in
patients with asthma. These effects of LABA may compensate for
relative resistance of neutrophil inﬂammation to corticosteroids in
COPD and severe asthma. On the other hand, corticosteroids may
also compensate for shortcomings of LABA. For example, LABAs
(and short-acting β2-adreneoceptor agonists) were shown to induce
in vitro a prolong survival of eosinophils, inhibiting their apoptosis, a
potentially harmful mechanism in asthma, that however, seems to
be totally reversed by corticosteroids [55]. Indeed, Kelly et al. [45]
have shown that in asthmatic subjects, allergen-induced sputum
eosinophilia was reduced by the combination of inhaled budesonide
and formoterol treatment even to a greater extent than by bude-
sonide alone.
Both COPD and severe asthma are characterised by enhanced
oxidative stress and production of reactive oxygen species (ROS)
by inﬂammatory and structural airway cells, aggravating inﬂamma-
tion and causing airway tissue injury and remodelling. ROS can also
decrease the number and function of β2-adrenoceptors in lung
tissue, and impair steroid receptor function. Formoterol and
salmeterol were shown to reduce ROS generation in neutrophils
and eosinophils in vitro and in vivo [56–63] and in cooperation with
corticosteroids [64]. Principally, leukocytes have a relatively low
number of β2 adrenoceptors which may be further decreased under
inﬂammatory conditions and oxidative stress. Therefore partial
agonists, such as salmeterol, may be not effective or may not be
able to reach full effects in these cells disregarded of how high
doses are used. Indeed, formoterol in a concentration-dependent
manner inhibited ROS generation (induced by LTB4) in guinea pig
peritoneal eosinophils while salmeterol had no effect at any concen-
trations and pre-incubation times investigated [56]. Signiﬁcantly, in
that study, salmeterol competitively antagonised inhibition exerted
by formoterol; so salmeterol acted as an antagonist in eosinophils.
Recently, Rossios et al [68] have shown that oxidative stress reduced
the level of β2-adrenoceptors in the cell membrane of mononuclear
cells and decreased salmeterol-induced cAMP production while it
did not affect signiﬁcantly cAMP induced by formoterol. Formoterol
also restored corticosteroid sensitivity reduced in these cells by
oxidative stress whereas salmeterol was less effective even at 100
times higher concentration. Furthermore, in Rossios et al study,
although both formoterol (1 nM) and salmeterol (100 nM) reversed
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insensitivity to corticosteroid treatment in peripheral blood
mononuclear cells (PBMCs) from subjects with severe asthma, only
formoterol restored corticosteroid sensitivity in PBMCs from COPD
subjects and increased signiﬁcantly cAMP production in these cells.
The authors concluded that, under conditions of high oxidative stress
such as COPD, formoterol, combined with corticosteroids, should be
more effective than salmeterol.
LABAs are often administered with ICS and it is now clear that
both drug classes affect airway function at multiple levels, including
an integrated effect on several cell types. LABAs and glucocortico-
steroids were long thought to act in parallel at different cells, but
now it is clear that they also work in concert at the same type of
cells, in an additive or synergistic manner, or each alleviating the
shortcomings of the other. The interaction between LABA and ICS
is often synergistic and may even create a self-enhancing
cycle at the level of β2-adrenoceptor and glucocorticosteroid
receptor expression and their signallinig pathways [65,66]. In
many cells the effects of β2-adrenoceptor agonists seem to
involve glucocorticosteroid receptor. Eickelberg et al [67]
demonstrated that β2-adrenoceptor agonists are able to translocate
glucocorticosteroid receptor to the cell nucleus. This has been ob-
served in vitro with both salmeterol and formoterol in various
human cells, such as lung ﬁbroblasts [67], vascular smooth muscle
cells [67] and airway smooth muscle cells [43]. However, it does
not seem to occur in cultured human bronchial epithelial
cells where neither formoterol nor salmeterol translocated
glucocorticosteroid receptor [68]. On the other hand, Usmani et al
[69] reported that in sputum epithelial cells (and macrophages),
combination therapy with salmeterol and ﬂuticasone propionate in
asthmatics augmented nuclear localisation of glucocorticosteroid re-
ceptor compared to ﬂuticasone alone. Essentially, both formoterol
and salmeterol synergistically enhance glucocorticosteroid-
dependent transcription in human airway epithelial and smooth
muscle cells [60] which may be important to counteract insensitivity
to glucocorticosteroids in severe asthma and COPD.
4. LABA and clinical management of chronic respiratory diseases
The prompt symptoms relief is one of the principal goals both in
asthma and in COPD. In COPD, morning symptoms, including
dyspnea and sputum production, affect quality of life and limit the
ability to perform even simple activities. It is emerging that these
symptoms are associated with increased risk of exacerbations and
work absenteeism, suggesting that they have a more profound
impact on patients than previously thought [70]. This makes rapid
onset of action an essential characteristic for a bronchodilator also
in COPD symptoms management. Recently, Cazzola et al evaluated
the onset of effect of a single-dose of formoterol (9 μg) versus a
single-dose of salmeterol (50 μg) in patients with moderate COPD
in a multicentre, double-blind, double-dummy, placebo-controlled,
three-way single-dose crossover study [71]. The increase in FEV1 at
5 min post-dose versus pre-dose was 7.2% for formoterol, 4.1% for
salmeterol and 0.7% for placebo, and signiﬁcantly greater for
formoterol versus salmeterol (ratio of treatment effects: 1.030; 95%
CI 1.008–1.052; p = 0.009). Moreover, the proportions of patients
with ≥12% increase in FEV1 at 5 min post-dose were 23.1%, 9.2%
and 6.4% for formoterol, salmeterol and placebo, respectively;
this was signiﬁcantly larger after formoterol than salmeterol (p =
0.008) or placebo (p b 0.001). The number of patients with adverse
events as well as the frequency of adverse events were low, both
with formoterol and salmeterol, and none of the adverse events
fulﬁlled any criteria for a serious adverse event [71]. Another study
of Cazzola et al explored whether the acute addition of an ICS
inﬂuenced the fast bronchodilator response to formoterol in stable
COPD [72]. The results demonstrated that over 60 min explored
after a single dose of budesonide/formoterol (2 × 160/4.5 μg) or
formoterol alone, both treatments induced a signiﬁcant improve-
ment over baseline at each time point investigated, however, mean
increases in FEV1 were always higher after budesonide/formoterol
than formoterol alone (for example, 50 ml higher 15 min after inha-
lation). The area under the FEV1 curve (AUC) after budesonide/
formoterol was signiﬁcantly larger than that after formoterol alone
both during the ﬁrst 15 min and the whole 60 min period explored.
Both treatments induced a signiﬁcant reduction in a dyspnea
visual analogue scale (VAS) score but did not modify heart rate in a
statistically signiﬁcant manner. This study indicates that the
addition of budesonide enhances the fast bronchodilatory action of
formoterol without inducing systemic effects. [72].
Many COPD studies have evaluated the long-term effects of LABA
and their combinations with ICS. Considering that bronchodilators
are pivotal in the management of COPD symptoms, long-acting
preparations being preferred when symptoms are persistent [4]. A
recent meta-analysis by Cope et al compared the efﬁcacy of
long-acting bronchodilators in patients with moderate to severe
COPD, in terms of lung function, health status, and dyspnoea [73].
Fifteen studies with salmeterol were included (10 vs placebo, 3 vs
tiotropium and 2 vs indacaterol), whereas 5 were included with
formoterol (4 vs placebo and 1 vs indacaterol). Thresholds for
clinically important differences were established for active
treatments versus placebo in terms of FEV1, total St. George's
Respiratory Questionnaire (SGRQ) score, and total Transitional
Dyspnea Index (TDI) score. At 6 months, formoterol treatment
resulted in 80–90% higher probability of increasing the proportion
of patients showing improvements in the TDI and SGRQ scores
as compared to salmeterol. Moreover, with 88% probability
formoterol treatment was more efﬁcacious than salmeterol in
improving the total SGRQ score at 6 months [73].
In more severe patients the use of a triple combination with
inhaled corticosteroid, LABA and long-acting muscarinic antagonist
(LAMA) is often adopted. Welte et al [74] evaluated the efﬁcacy
and tolerability of budesonide/formoterol added to tiotropium
during a 12-week period in 660 COPD patients with a mean FEV1
of 38% of predicted value and eligible for inhaled ICS/LABA
combination therapy. This study demonstrated that budesonide/
formoterol added to tiotropium versus tiotropium alone provided
more rapid and sustained improvements in lung function, health
status, morning symptoms and activities, and reduced severe exacer-
bations [74]. Similarly, Aaron et al. investigated whether combining
tiotropium with ﬂuticasone/salmeterol or with salmeterol only, im-
proves clinical outcomes in adults with moderate to severe COPD
compared with tiotropium alone. Tiotropium plus ﬂuticasone/
salmeterol improved lung function and disease-speciﬁc quality of
life and reduced the number of hospitalisations for COPD exacerba-
tion and all-cause hospitalisations compared with tiotropium plus
placebo. In contrast, tiotropium plus salmeterol did not statistically
improve lung function or hospitalisation rates compared with
tiotropium plus placebo [75].
Regarding asthma treatment, both formoterol and salmeterol
when added to ICS treatment, reduce asthma exacerbations. However,
the systematic review and meta analysis of parallel-group, blinded,
randomised, controlled trials with at least 12 weeks of treatment in
patients concomitantly using ICS, showed that only formoterol, but
not salmeterol, reduced signiﬁcantly asthma-related hospital admis-
sions when compared with placebo at the similar dose of ICS used
[76]. Similarly, in the largest double-blind study comparing ﬁxed-dose
combination therapy with budesonide/formoterol versus ﬂuticasone/
salmeterol at equivalent ICS doses, budesonide/formoterol treatment
resulted in a statistically signiﬁcant 32% lower rate of asthma-related
hospitalisations/emergency room visits [77].
The fast onset of action of formoterol, as fast as for short-acting β2
adrenoceptor agonists [78], allowed introducing a new treatment
concept in asthma where budesonide/formoterol combination in one
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inhaler (Symbicort®) is used as Symbicort Maintenance and Reliever
Therapy (SMART®). In this therapy, patients inhale budesonide/
formoterol from one inhaler once or twice daily and whenever they
feel a need of using a rapid acting bronchodilator to relieve symptoms.
The SMART® therapy has been extensively validated in randomised
controlled clinical trials [79] as well as has been shown to be valid in
daily clinical practice [80]. Efﬁcacy and safety data on this strategy are
consistent and is worldwide considered a relevant to in reducing the
exacerbation and the overall dose of inhaled steroid needed [81,82].
5. Conclusions
The evidence published in the last decades support the fundamental
role of long-acting β2 adrenoceptor agonists both in asthma (always
combined with inhaled steroid) and in COPD and highlighted many
additional effects which are not related to bronchodilation. Although
similar outcomes can be achieved by formoterol and salmeterol, at
similar safety proﬁle, the fast onset of action and the full agonism of
formoterol need to be considered when selecting the best pharma-
cological treatment of asthma and COPD.
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